[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100647282":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":24,"locations":10,"responsibleParty":30,"collaborators":10,"id":32,"slug":33,"hasResults":34,"nctId":35,"briefTitle":36,"officialTitle":37,"acronym":38,"eligibilityCriteria":39,"healthyVolunteers":34,"sex":40,"minAge":41,"maxAge":10,"enrollmentInfo":42,"targetDuration":45,"studyType":46,"phases":10,"briefSummary":47,"conditions":48,"keywords":51,"overallStatus":56,"whyStopped":10,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":10},{"fullName":5,"class":6},"Ataraxis AI, Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Ataraxis testing",null,"Adult patients with a solid tumor malignancy undergoing Ataraxis testing as part of routine clinical care. Treatment will be at the discretion of the physician.",[13],"Diagnostic Test: Ataraxis testing",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":10},"DIAGNOSTIC_TEST","Ataraxis AI's digital pathology-based artificial intelligence (AI) testing, ordered as part of routine clinical care.",[9],[20],{"name":21,"affiliation":22,"role":23},"Jan Witowski, MD, PhD","Ataraxis AI","STUDY_DIRECTOR",[25],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},"Halle Hall","CONTACT","+1 (646) 832-2265","halle.hall@ataraxis.ai",{"type":31,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100647282","ataraxis-real-world-clinical-outcomes-registry-linking-ai-based-pathology-scores-to-patient-outcomes-100647282",false,"NCT07706842","Ataraxis Real-World Clinical Outcomes Registry Linking AI-Based Pathology Scores to Patient Outcomes","Ataraxis Real-World Clinical Outcomes: A Prospective, Multi-Site, Observational Registry Linking AI-Based Pathology Scores With Short- and Long-Term Outcomes","ARC","Inclusion Criteria:\n\n* Aged 18 years or older at the time of consent.\n* Diagnosis of a solid tumor malignancy, confirmed histologically or cytologically.\n* Patient is undergoing Ataraxis testing as part of their routine clinical care.\n* Availability of a pathology specimen.\n* Willing and able to provide written informed consent.\n\nExclusion Criteria:\n\n* Unable or unwilling to provide informed consent.\n* Patient for whom an Ataraxis test result was not successfully generated (e.g., due to sample quality, technical failure, or any reason resulting in a non-reportable result).","ALL","18 Years",{"count":43,"type":44},1000,"ESTIMATED","10 Years","OBSERVATIONAL","The ARC Registry is a large-scale, multi-site, prospective, observational registry. All patients with a solid tumor malignancy who receive Ataraxis testing as part of routine clinical care are eligible for enrollment, which will link Ataraxis test results with short- and long-term patient outcomes to evaluate the real-world performance and clinical utility of Ataraxis tests. The ARC Registry utilizes an adaptable design, where additional Sponsor-led analyses and investigator-initiated ancillary studies can be added after the initial study is opened.",[49,50],"Solid Tumor Malignancy","Breast Cancer",[52,53,54,55],"breast cancer","artificial intelligence","registry","digital pathology","NOT_YET_RECRUITING","2026-07-10",{"date":59,"type":60},"2026-07-16","ACTUAL",{"date":62,"type":44},"2026-07-31",{"date":64,"type":44},"2038-12",{"name":5,"class":6}]